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Quantification of active mitochondrial permeability transition pores using
GNX-4975 inhibitor titrations provides insights into molecular identity
Andrew P. Richardson* and Andrew P. Halestrap*1
*School of Biochemistry and Bristol CardioVascular, University of Bristol, Medical Sciences Building, University Walk, Bristol BS8 1TD, U.K.
Inhibition of the mitochondrial permeability transition pore
(MPTP) by the novel inhibitor GNX-4975 was characterized.
Titration of MPTP activity in de-energized rat liver mitochondria
allowed determination of the number of GNX-4975-binding sites
and their dissociation constant (K i). Binding sites increased
in number when MPTP opening was activated by increasing
[Ca2 + ], phenylarsine oxide (PAO) or KSCN, and decreased when
MPTP opening was inhibited with bongkrekic acid (BKA) or
ADP. Values ranged between 9 and 50 pmol/mg of mitochondrial
protein, but the K i remained unchanged at ∼1.8 nM when the
inhibitor was added before Ca2 + . However, when GNX-4975 was
added after Ca2 + it was much less potent with a K i of ∼140 nM.
These data imply that a protein conformational change is required
to form the MPTP complex and generate the GNX-4975-binding
site. Occupation of the latter with GNX-4975 prevents the
Ca2 + binding that triggers pore opening. We also demonstrated
that GNX-4975 stabilizes an interaction between the adenine
nucleotide translocase (ANT), held in its ‘c’ conformation with
carboxyatractyloside (CAT), and the phosphate carrier (PiC)
bound to immobilized PAO. No components of the F1Fo-ATP
synthase bound significantly to immobilized PAO. Our data
are consistent with our previous proposal that the MPTP may
form at an interface between the PiC and ANT (or other
similar mitochondrial carrier proteins) when they adopt novel
conformations induced by factors that sensitize the MPTP to
[Ca2 + ]. We propose that GNX-4975 binds to this interface
preventing a calcium-triggered event that opens the interface into
a pore.
Key words: adenine nucleotide translocase, calcium, inhibition,
mitochondrial permeability transition pores, mitochondrial
phosphate carrier, molecular mechanism.
INTRODUCTION
The mitochondrial permeability transition pore (MPTP) is a large
non-specific channel in the inner mitochondrial membrane (IMM)
whose opening is triggered by high matrix [Ca2 + ] to which it can
be sensitized by a variety of factors. These include elevated [Pi],
adenine nucleotide depletion, agents such as carboxyatractyloside
(CAT) that stabilize the adenine nucleotide translocase (ANT)
in its cytoplasmic facing (‘c’) conformation, mild chaotropic
agents such as KSCN and oxidative stress or its chemical mimic
phenylarsine oxide (PAO) [1]. It is now widely accepted that
MPTP opening plays a central role in the cell death that underlies
several pathological conditions including ischaemia/reperfusion
injury [2–5]. However, the exact molecular composition of the
MPTP remains unresolved [1,4,6,7]. There is general agreement
that the matrix peptidyl prolyl cis–trans isomerase cyclophilin
D (CyP-D) acts as key regulator of the MPTP, enhancing its
sensitivity to [Ca2 + ]. Indeed, CyP-D is the site of action of two
potent inhibitors of MPTP opening, cyclosporin A (CsA) and
sanglifehrin A (SfA), both of which protect cells from death
mediated by MPTP opening such as in ischaemia/reperfusion
injury [3]. However, the molecular composition of the IMM
components of the MPTP, with which CyP-D interacts, remains
controversial.
Studies from our and other laboratories have implicated the
ANT and the phosphate carrier (PiC), both of which can bind CyP-
D [8–11] and whose ligands modulate MPTP opening [10,12–
14]. Indeed the ANT, when reconstituted into phospholipid
membranes, does demonstrate calcium-activated pore formation
that can be modulated by CyP-D [9,15,16]. However, knockdown
of either the PiC or ANT does not prevent MPTP opening,
although the response to calcium and ANT ligands is severely
attenuated [11,17,18]. More recently, others have proposed a role
for the F1Fo-ATP synthase which can also interact with CyP-
D [19], although there are competing hypotheses as to which
subunits are involved. Data from the laboratories of Pinton [20]
and Jonas [21] have implicated the c subunits of the Fo ATP
synthase, whereas Bernardi and colleagues propose a role for
dimers of the F1Fo-ATP synthase, perhaps involving subunits
associated with the c-ring in the membrane such as a, e, f, g
and A6L moving to produce the pore [4,22]. We and others
have expressed reservations about such a role for the F1Fo-
ATP synthase since a considerable body of evidence is better
explained by interactions of pore regulators with the ANT and
PiC [1,6,23]. Nevertheless, it remains possible that an interaction
between the ANT, PiC and ATP synthase is involved in MPTP
formation and such interactions may occur in the ATP synthasome
[1,6,24,25]. Most recently evidence has been presented for the
mitochondrial AAA protease SPG7 (spastic paraplegia 7) being
essential for MPTP opening [26], although others have questioned
these conclusions [27].
The role of CyP-D in mediating MPTP opening was first
demonstrated in our laboratory by performing CsA inhibitor
titrations of MPTP opening and the peptidyl prolyl cis–trans
isomerase activity of CyP-D. These demonstrated that the K i for
CsA inhibition of both actions was the same (∼5 nM) and that
Abbreviations: ANT, adenine nucleotide translocase; BKA, bongkrekic acid; CAT, carboxyatractyloside; CsA, cyclosporin A; CyP-D, cyclophilin D; IMM,
inner mitochondrial membrane; ISB, isolation buffer; MCF, mitochondrial carrier family; MPTP, mitochondrial permeability transition pore; NTA, nitrilotriacetic
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the high affinity of binding allowed calculation of the number of
CsA-binding sites which were also identical for both processes
[28,29]. Recently, Congenia has developed a new class of highly
potent cinnamic anilide-based inhibitors of MPTP opening that
protect against ischaemia/reperfusion injury of the heart [30] and
amyotrophic lateral sclerosis [31]. Although the generic structure
of these inhibitors is available [31,32], the exact structure of
GNX-4975 is not in the public domain. MPTP inhibition by
these agents does not involve CyP-D, implying that they must
interact with another component of the MPTP. In the present
study, we explore the binding site of the inhibitors in more detail
using GNX-4975 which we demonstrate to have a K i for MPTP
inhibition of ∼2 nM under a variety of conditions. Importantly,
we show that the number of binding sites for GNX-4975 increases
when MPTP opening is activated by PAO or KSCN, and decreases
when MPTP opening is inhibited with bongkrekic acid (BKA) or
ADP. These data imply that a protein conformational change is
required to form the MPTP and that this generates the binding site
for GNX-4975. We further demonstrate that GNX-4975 enhances
the association of ANT to the PAO-bound PiC. This is consistent
with our previous proposal that an interface between the PiC and
ANT may occur when these proteins adopt novel conformations
induced by factors that sensitize the MPTP to [Ca2 + ] [1]. We
propose that GNX-4975 binds to this interface preventing a
calcium-triggered event that opens the interface into a pore.
EXPERIMENTAL
Materials
Unless otherwise stated, all chemical and biochemicals were
obtained from Sigma–Aldrich or Fisher Scientific. Antibodies
against the C-terminus of the ANT and PiC were raised either
in-house or commercially as described in [10]. The use of rats
conformed to the U.K. Animals (Scientific Procedures) Act 1986
and was approved by the appropriate University of Bristol ethics
committee (UB/09/012).
Mitochondria were prepared from livers of 250–275 g male
Wistar rats by Dounce Potter homogenization in sucrose isolation
buffer (ISB: 300 mM sucrose, 10 mM Tris/HCl and 2 mM EGTA,
pH 7.4) followed by differential centrifugation and Percoll®
density-gradient centrifugation as described previously [28].
Preparation of beef and pig heart mitochondria involved initial
tissue disruption with a Polytron 10-35 GT homogenizer [10]
with subsequent steps being the same as for liver mitochondria.
For measurement of MPTP opening in de-energized rat liver
mitochondria, they were routinely prepared 1 day before they
were used to assay MPTP opening and stored overnight on ice.
This avoided changes to the [Ca2 + ] sensitivity of the MPTP caused
by progressive loss of total adenine nucleotides over the first few
hours of storage on ice [12,32].
Methods
Measurement of MPTP opening in de-energized mitochondria
This was performed by one of two techniques. A swelling assay
was used in which pore opening was triggered by addition of Ca2 +
[12,28]. In addition a shrinkage assay was employed in which pre-
swollen mitochondria were incubated with the required [Ca2 + ]
to open the MPTP, the extent of which was then determined
by the rate of shrinkage induced by addition of polyethylene
glycol (PEG) [32]. In both cases the initial rate of decrease
(swelling) or increase (shrinkage) in light scattering (monitored
as A520) was used to determine the extent of MPTP opening. For
the swelling assay, mitochondria were incubated at 25 ◦C and
0.5–1 mg of protein/ml in de-energized assay buffers containing
either 150 mM KSCN or 125 mM KCl plus 2.5 mM potassium
phosphate as the osmotic support and 20 mM MOPS, 10 mM
Tris/HCl, 2 mM nitrilotriacetic acid (NTA), 0.5 μM rotenone,
0.5 μM antimycin A and 2 μM A23187 at pH 7.2. MPTP opening
was initiated by addition of [Ca2 + ] (usually 50 μM free) and
A520 was monitored continuously in a spectrophotometer with
computerized data acquisition. When GNX-4975 was included,
it was added 2 min prior to the addition of Ca2 + , whereas
incubations with other drugs or reagents were carried out for
4 min prior to the addition of Ca2 + .
For the shrinkage assay, mitochondria (2 mg/ml) were pre-
swollen by incubation for 20 min at 30 ◦C in standard de-energized
KSCN buffer (as above) but without added NTA or A23187
and with addition of 1 mM CaCl2. Any residual swelling was
terminated by an addition of 1.2 mM EGTA, which also resealed
swollen mitochondria. The resulting swollen mitochondria were
collected by centrifugation at 12 000 g for 10 min and resuspended
at 2 mg/ml in de-energized KSCN buffer without added NTA
or A23187. In order to ensure equilibrium of matrix with the
buffer, the swollen mitochondria were incubated again at 30 ◦C
supplemented with 1 mM CaCl2. After 3 min, 1.2 mM EGTA was
added to reseal the mitochondria before centrifugation at 12 000 g
for 10 min. The swollen mitochondria were then resuspended at
30 mg/ml in de-energized KSCN buffer containing 2 mM NTA
and 2 μM A23187 and stored on ice. The extent of MPTP opening
in these pre-swollen mitochondria was determined following
incubation at 0.33 or 0.67 mg/ml for the stated time in KSCN
or KCl buffer containing, where indicated, the required [GNX-
4975] and free [Ca2 + ] (calculated as described in [33]). Shrinkage
was initiated by rapid addition of 0.5 ml of 50% (w/v) PEG (to
give a final PEG concentration of 7%, w/v) and was continuously
monitored (ten data points per second) as an increase in A520.
Determination of the number of binding sites and K i for GNX-4975
inhibition of the MPTP
The initial rate of swelling or shrinking of mitochondria pre-
incubated with increasing concentrations of GNX-475 was
determined by differentiation of the time course of A520 change.
As described previously [34,35], the data were then fitted using
FigSys (BioSoft) to the equation for the inhibition of rate by a
tight binding inhibitor:
V = k · Et · P − k ·
(
B − √B · B − 4 · C)
2
whereB = Et · P + I + K i
and C = Et · P · I
Et represents the number of GNX-4975-binding sites in pmol/mg,
P is the mitochondrial protein concentration (mg/ml), K i is
the dissociation constant for GNX-4975 (nM) and k is the
rate constant for swelling (A520 · s− 1 · nM− 1). Unless otherwise
stated, for each titration, a separate Et, K i and k were derived and
the mean value +− S.E.M. calculated for several mitochondrial
preparations (n = 3–6 as indicated). In order to correct for
variations in the rates of swelling or shrinking determined using
different mitochondrial preparations on different days, rates at
any particular inhibitor concentration were usually calculated as
a percentage of the maximal rate of swelling in the absence of
inhibitor or other MPTP modulating reagents. In this case, the k
value becomes 100/Et and so its value is not presented.
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
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Measurement of MPTP opening in energized mitochondria
This was performed by simultaneously measuring extra-
mitochondrial [Ca2 + ] with Fura-FF fluorescence, membrane
potential with Rhodamine 123 fluorescence and mitochondrial
swelling with light scattering at 490 nm as described previously
[14]. The incubation medium consisted of 125 mM KCl, 10 mM
Tris/HCl, 20 mM MOPS, 2.5 mM potassium phosphate, 5 mM
L-glutamate, 2 mM L-malate, 20 μM EGTA, 0.1 μM Fura-FF and
100 nM Rhodamine-123, pH 7.2, at 30 ◦C. MPTP opening was
induced by sequential additions of Ca2 + as indicated in the figures.
Preparation and solubilization of inner mitochondrial membranes
Centrifugation steps in this process were carried out using a
benchtop Eppendorf 5415R centrifuge at 4 ◦C. Mitochondria were
washed in ISB and centrifuged at 12 000 g for 5 min before re-
suspension in ISB containing protease inhibitors (4 μg/ml each
of antipan, pepstatin A and leupeptin plus 0.5 mM benzamidine
and 0.5 mM PMSF). Mitochondria were incubated with digitonin
(0.12 mg/mg of mitochondrial protein) at 4 ◦C for 15 min
on a rotary mixer, and the resulting mitoplasts collected by
centrifugation at 9000 g for 10 min before resuspension in ISB
containing protease inhibitors and PEG ether W1 (Sigma P7516,
formerly known as Lubrol) at 0.16 mg/mg of mitochondrial
protein. The mixture was incubated at 4 ◦C for 15 min on a rotary
mixer and insoluble material removed by centrifugation at 4000 g
for 30 s. The supernatant was centrifuged at 125 000 g and 4 ◦C
for 30 min in a Beckman OptimaTM TLX ultracentrifuge (TLA-
55 rotor) to yield the IMM pellet. Where required, pre-treatment
of mitochondria with drugs or reagents was performed in ISB
at a protein concentration of 2 or 5 mg/ml for 10 min at room
temperature with constant agitation. The treated mitochondria
were collected by centrifugation at 12 000 g for 5 min and re-
suspended in ISB containing protease inhibitors (as above), prior
to digitonin treatment. Where indicated, drugs or reagents were
present throughout the duration of the isolation, including the
Lubrol treatment.
Binding of solubilized IMM proteins to immobilized phenylarsine
oxide
An immobilized PAO matrix was synthesized by coupling 4-
aminophenylarsine oxide to Affi-gel 10 (Bio-Rad Laboratories
153-6099) as described previously [10,12]. The resin was
washed twice in 10 volumes of PAO column buffer (PCB:
150 mM Na2SO4, 50 mM HEPES and 1 mM EGTA, pH 7.2)
containing 0.5% (v/v) Triton X-100 and then resuspended
to give a 50% (v/v) slurry ready for use. IMM fractions
from mitochondria incubated with the required reagents were
resuspended in PCB containing 1% (v/v) Triton X-100 and
protease inhibitors (as above) and solubilized for 1 h on a
rotary mixer at 4 ◦C. Insoluble material was removed by
centrifugation at 16 000 g for 12 min and the supernatant
transferred to prepared aliquots of pre-washed 50% slurry of
PAO beads (200 μl/1 per mg of solubilized protein) and in-
cubated for 1 h on a rotary mixer at 4 ◦C. Beads were collected by
centrifugation at 200 g for 1 min and were washed five times with
1 ml of PCB containing 3% (v/v) Triton X-100 to remove non-
specifically bound proteins. Specifically bound proteins were then
eluted by incubating in 80 μl of 25 mM DTT in PCB containing
1% (v/v) Triton X-100 for 30 min on a rotary mixer at 4 ◦C.
Beads were collected by centrifugation at 2000 g for 3 min and the
supernatant (70 μl) was added to an equal volume of SDS/PAGE
sample buffer. Samples were analysed by SDS/PAGE and Western
blotting or analysed by Orbitrap MS in the University of Bristol
Proteomics Facility. Development of Western blots was performed
using ECL with film detection of the emitted light and analysis of
the scanned film with ImageJ software (http://imagej.nih.gov/).
The integrated optical density for each band was calculated as
the product of the ‘area’ and ‘mean grey value’ with subtraction
of a background signal obtained for an equivalent adjacent area
lacking any band. In one set of experiments comparative analysis
was performed using direct detection of ECL with an ODDESEY
Fc (LI-COR) and analysis of the bands performed using Image
Studio (LI-COR). The band intensities were determined by the
software and corrected for background by subtracting the mean
signal of five pixels above and below each band of interest.
RESULTS
GNX-4975 is a tight binding inhibitor of the MPTP
We first confirmed that GNX-4975 is a potent inhibitor
of MPTP opening in energized liver mitochondria by
simultaneously measuring extra-mitochondrial [Ca2 + ] (Fura-FF
fluorescence), membrane potential (Rhodamine 123 fluorescence)
and mitochondrial swelling (light scattering at 490 nm) as
described previously [14]. As shown in Supplementary Figure S1,
sequential additions of Ca2 + were taken up by the mitochondria
until the MPTP opened, at which time the accumulated Ca2 +
was released, the membrane potential was dissipated and the
light scattering rapidly decreased as the mitochondria swelled. In
control mitochondria, this occurred after addition of 70–80 μM
Ca2 + , whereas in the presence of 0.2 μM GNX-4975 MPTP
opening required 200–240 μM Ca2 + .
In order to determine an accurate concentration-dependence
of MPTP inhibition by GNX-4975, we employed de-energized
mitochondria in the presence of a Ca2 + ionophore (A23187),
since this avoids any complications that might be caused by
secondary effects of the drug on mitochondrial energization or
calcium transport. We also performed the assays in medium
containing 150 mM KSCN since we have previously shown that
this mildly chaotropic buffer promotes the active conformation of
the MPTP and generates very consistent data [32]. GNX-4975
was added at the required concentration to the mitochondrial
suspension 2 min before Ca2 + was added to initiate MPTP
opening whose extent was determined from the initial rate of
swelling (decrease in A520) quantified by taking the first derivative
of each time course. Figure 1 shows mean data (+−S.E.M.) for
such inhibitor titrations on six separate mitochondrial preparations
each used at two different concentrations of mitochondria (0.5 and
1 mg of protein/ml). It is immediately apparent that more GNX-
4975 was required to give 50% inhibition at the higher protein
concentration as is predicted for a very tight binding inhibitor
whose K i value is less than the concentration of binding sites.
This was observed previously for CsA inhibition of MPTP
opening and using the appropriate equation for inhibition by a
tight binding inhibitor this allowed calculation of the true K i
(dissociation constant) for inhibitor binding and the number of
inhibitor-binding sites (Et) [28,29]. We successfully analysed
the data of Figure 1 in this way and determined Et to be
12.6 +− 1.7 pmol/mg and the dissociation constant for drug binding(K i) to be 1.95 +− 0.17 nM (values presented as means +− S.E.M.
for six separate mitochondrial preparations). It should be noted
that absolute values of light scattering are not linearly related
to mitochondrial protein concentration and can also vary from
day to day. Thus, to analyse the data from several experiments,
the rates of swelling in the absence of inhibitor at 0.5 and
1 mg/ml mitochondrial protein were set at 50 and 100 respectively
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
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Figure 1 GNX-4975 is a tight binding inhibitor of the MPTP
Opening of the MPTP in isolated aged liver mitochondria under de-energized conditions in KSCN
medium was induced by 50 μM Ca2 + and the initial rate of change in A 520 was determined
as described in the Experimental section. For each concentration of GNX-4975, two protein
concentrations were employed (0.5 and 1 mg/ml) and rates of swelling were expressed as a
percentage of the zero inhibitor rate for which the value at 0.5 mg/ml protein was normalized
to 50 % of that at 1 mg of protein to overcome the lack of linearity of A 520 with protein
concentrations. Data are shown as means +− S.E.M. (error bars) for six different mitochondrial
preparations, each of which was fitted to the tight binding inhibitor equation to calculate the
number of inhibitor-binding sites (E t) and their K i value. The fitted line was calculated using
the derived mean values (+−S.E.M.) for E t (12.6 +− 1.7 pmol/mg) and K i (1.95 +− 0.17 nM).
and values at each concentration of GNX-4975 were calculated
relative to the control value.
MPTP activation increases the number of GNX-4975-binding sites
without affecting their K i
The data shown in Figure 2A compare the inhibition profile of
GNX-4975 in KSCN medium, which activates the MPTP, with
data obtained in a more physiological KCl-based medium contain-
ing 125 mM KCl and 2.5 mM potassium phosphate. It is immedi-
ately apparent that rates of swelling at zero inhibitor are less in the
KCl medium (set at 100%) than in KSCN medium, whereas the
derived K i values (mean +− S.E.M. for five separate experiments)
were similar, being 1.68 +− 0.13 and 2.29 +− 0.17 nM respectively.
However, the calculated number of GNX-4975-binding sites in
the KSCN buffer (19.2 +− 2.2 pmol/mg) was significantly higher(P < 0.01) than in the KCl buffer (9.43 +− 1.4 pmol/mg). It should
be noted that in these experiments, in order to ensure that rates of
swelling in KCl medium were sufficiently rapid to allow accurate
inhibitor titrations, we activated MPTP opening with 150 μM
Ca2 + . As discussed further below, this explains the higher value
of Et than determined in Figure 1 where only 50 μM Ca2 + was
employed. These data suggest that activation of the MPTP by
KSCN involves an increase in the active conformation of the pore
to which GNX-4975 binds. It should be noted that it is not possible
to relate the rates of swelling directly to the number of binding
sites because many additional factors can affect the absolute value
of A520 as noted above.
Activation of the MPTP can also be achieved by exposing the
mitochondria to oxidative stress and this can be mimicked by the
vicinal thiol reagent PAO [12,36], which acts, at least in part,
by cross-linking thiol groups on the ANT and PiC [10,12,37]. In
Figure 2B we show that, following a short pre-incubation with
20 μM PAO, MPTP opening was activated as expected and that
this led to an increase in the number of binding sites for GNX-
4975 from 11.9 +− 0.92 to 17.2 +− 1.3 pmol/mg (means +− S.E.M.
for six separate mitochondrial preparations; P < 0.01) without
Figure 2 Increasing the propensity of the MPTP to open with either KSCN
buffer or PAO increases the number of GNX-4975-binding sites
Opening of the MPTP was measured as described in Figure 1 but for each separate
mitochondrial preparation a single protein concentration (1 mg/ml) was employed. In (A), parallel
measurements were made using either the standard 150 mM KSCN medium or one in which
the KSCN was replaced with 125 mM KCl + 2.5 mM potassium phosphate. For both media,
MPTP opening was initiated by addition of 150 μM Ca2 + and rates of swelling were expressed
as a percentage of the zero inhibitor rate in the KCl medium. Mean data +− S.E.M. (error bars) for
five separate mitochondrial preparations are given. Data were fitted as described in Figure 1 and
generated mean derived values (+−S.E.M., n = 5) for E t of 9.43 +− 1.4 and 19.2 +− 2.2 pmol/mg
in KCl and KSCN medium respectively (P 0.01 calculated using the unpaired Student’s t test).
The corresponding calculated K i values were 1.68 +− 0.13 and 2.29 +− 0.17 nM respectively. In
(B), mitochondria were either untreated (control) or pre-incubated with 20 μM PAO for 3 min
before addition of 50 μM Ca2 + in KSCN medium to initiate swelling. Mean data +− S.E.M.
(error bars) for six separate mitochondrial preparations are given. The rate of swelling in the
absence of both PAO and GNX-4975 was set at 100 and all other rates calculated relative to this.
Data, fitted as in (A) gave mean values (+−S.E.M.) for E t in the absence and presence of PAO
of 11.9 +− 0.92 and 17.2 +− 1.3 pmol/mg respectively (P < 0.01) with corresponding K i values
of 1.93 +− 0. 21 and 2.56 +− 0.14 nM.
any significant change in K i (1.93 +− 0.21 and 2.56 +− 0.14 nM
respectively). Conversely, BKA, an inhibitor of the ANT that traps
the carrier in its matrix facing (‘m’) conformation, inhibits MPTP
opening as does ADP which also favours the ‘m’ conformation
[12,13,38,39]. In Figure 3A, we show that mitochondrial pre-
treatment with 5 μM BKA decreased the number of GNX-
4975-binding sites from 13.2 +− 0.64 to 9.43 +− 0.47 pmol/mg(means +− S.E.M. for six separate mitochondrial preparations;
P < 0.001), again without any change in K i (1.45 +− 0.23
and 1.46 +− 0.16 nM respectively). In Figure 3B, we show
similar data for mitochondria pre-treated with 20 μM ADP
which decreased the number of GNX-4975-binding sites from
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
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Figure 3 The ‘m’ conformation of the ANT reduces the number of GNX-
4975-binding sites
Experiments were performed exactly as described for Figure 2B but with 3 min of pre-treatment
of either 5 μM BKA (A) or 20 μM ADP (B) prior to addition of 50 μM Ca2 + to initiate
swelling. Mean data +− S.E.M. (error bars) for six separate mitochondrial preparations are
given. The rate of swelling in the absence of both GNX-4975 and ADP or BKA was set at
100 and all other rates calculated relative to this. Data were fitted as described in Figure 1. In
(A) mean values (+−S.E.M.) for E t in the absence and presence of BKA were 13.2 +− 0.64 and
9.43 +− 0.47 pmol/mg (P < 0.001), whereas K i values remained unchanged (1.45 +− 0.23 and
1.46 +− 0.16 nM respectively). In (B), the derived values for E t in the absence and presence of
ADP were 14.1 +− 0.83 and 11.0 +− 0.97 pmol/mg (P < 0.05) with K i values of 1.57 +− 0.24 and
1.45 +− 0.15 nM respectively.
14.1 +− 0.83 to 11.0 +− 0.97 pmol/mg (means +− S.E.M. for six
separate mitochondrial preparations; P < 0.05), also without any
change in K i (1.57 +− 0.24 and 1.44 +− 0.15 nM respectively).
The number of GNX-4975-binding sites is increased when higher
[Ca2+ ] is used to induce MPTP opening
Increased [Ca2 + ] within the mitochondrial matrix is a key trigger
for MPTP opening and, under de-energized conditions, the
extent of MPTP opening can be increased progressively with
increasing [Ca2 + ] [12,32]. In Figure 4, we investigate the effect
of increasing the [Ca2 + ] used to trigger MPTP opening on the
number of GNX-4975-binding sites. When MPTP opening was
triggered with 150 μM [Ca2 + ], initial rates of swelling were
200 +− 7.9% of the rates at 50 μM [Ca2 + ] and the corresponding
number of GNX-4975-binding sites increased from 13.2 +− 2.4
to 20.9 +− 1.6 pmol/mg (means +− S.E.M. for five separate
Figure 4 The concentration of Ca2+ used to initiate MPTP opening affects
the number of GNX-4975-binding sites
Experiments were performed exactly as described for Figure 1, but at a single protein
concentration (1 mg/ml) and using either 50 or 150 μM Ca2 + to initiate swelling. The initial
rate of swelling induced by 50 μM Ca2 + in the absence of GNX-4975 was set at 100 and
all other rates calculated relative to this. Data for five separate mitochondrial preparations
were fitted as described in Figure 1 to derive mean values ( +− S.E.M.) of E t at 50 and 150 μM
Ca2 + of 13.2 +− 2.4 and 20.9 +− 1.6 pmol/mg respectively (P < 0.05). Corresponding K i values
remained unchanged at 1.91 +− 0.35 and 2.15 +− 0.26 nM respectively.
mitochondrial preparations; P < 0.05) without any significant
change in K i value (1.91 +− 0.35 and 2.15 +− 0.26 nM respectively).
These data imply that [Ca2 + ] may trigger MPTP opening by
inducing the open conformation to which GNX-4975 binds.
When swelling was employed to measure the extent of MPTP
opening, the assay is initiated by addition of Ca2 + . This places
limitations on studying the interaction between [Ca2 + ] and GNX-
4975 binding since the inhibitor must always be added before or at
the same time as Ca2 + . This limitation can be overcome by using
a different assay of MPTP opening in which mitochondria are pre-
swollen with Ca2 + and then caused to shrink by addition of PEG
2000 that is too large to permeate the MPTP. The PEG exerts
an osmotic pressure on the IMM that shrinks the mitochondria
at a rate (measured as an increase in A520) proportional to the
extent of MPTP opening [40,41]. In this assay, the MPTP is
opened by addition of Ca2 + prior to addition of PEG 2000
which allows GNX-4975 to be added either before or after Ca2 +
prior to determination of the extent of MPTP opening. We first
demonstrated that the shrinkage assay could be used to determine
the number and K i of GNX-4975-binding sites on the active
MPTP. Data are presented in Figure 5A where the concentration-
dependence of MPTP inhibition by GNX-4975 at two protein
concentrations is determined using this assay. The data were
fitted in exactly the same manner as the swelling data of Figure 1
and gave values of the number of binding sites for GNX-4975
of 46.9 +− 5.3 pmol/mg with a K i of 2.08 +− 0.30 nmol (mean +−
S.E.M. for three separate experiments). The number of GNX-
4975-binding sites is substantially higher than that observed in the
swelling data of Figure 1 (12.6 +− 1.7 pmol/mg), and this probably
reflects the formation of additional active MPTP complexes
during the pre-swelling of mitochondria induced by addition of
1 mM [Ca2 + ] in KSCN buffer which is accompanied by the loss
of intramitochondrial ATP and ADP, both of which inhibit MPTP
opening [12,13]. Importantly, however, the K i value for GNX-
4975 was very similar to that obtained in the swelling assay
(1.95 +− 0.17 nM).
We also used the shrinkage assay to compare the concentration-
dependence of GNX-4975 inhibition of MPTP opening in binding
in KCl and KSCN buffers to see whether the activation by KSCN
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Figure 5 Assay of MPTP opening by shrinking of pre-swollen mitochondria
confirms GNX-4975 to be a tight binding inhibitor and that activation of the
MPTP by KSCN is reversible
Pre-swollen mitochondria (1 or 2 mg) were incubated with increasing concentrations of
GNX-4975 for 1 min in a cuvette containing 3 ml of KSCN or KCl medium. Ca2 + (50 μM) was
then added and, after a further 1 min, shrinkage was initiated by addition of 500 μl of 50 %
(w/v) PEG 2000 followed by rapid mixing. Initial rates of increase in A 520 were determined as
described in the Experimental section. In (A), data are presented as means +− S.E.M. (error bars)
for four separate mitochondrial preparations used at either 1 or 2 mg of protein per cuvette as
indicated. Rates of swelling are expressed as a percentage of the zero inhibitor rate for each
protein concentration and then values for 1 mg of protein are expressed as 50 % of those at
2 mg of protein. This overcomes the lack of linearity of A 520 with protein concentrations when
fitting the data to the tight binding inhibitor equation using both sets of data. The mean derived
values for the number of inhibitor binding sites and their K i value were 46.9 +− 5.3 pmol/mg and
2.08 +− 0.30 nM respectively. In (B), pre-swollen mitochondria (2 mg total) were incubated in a
KSCN or KCl medium, as indicated, containing the required concentrations of GNX-4975 and
Ca2 + (50 μM) was added before initiating shrinkage by addition of PEG 2000. All initial rates of
shrinking are expressed as a percentage of the rate in KSCN medium in the absence of inhibitor.
Data are shown as means +− S.E.M. (error bars) for three separate mitochondrial preparations
and were fitted as above. The derived values (+−S.E.M. for the fit shown) for the number of
inhibitor-binding sites in KSCN and KCl assay media were 49.0 +− 2.8 and 29.6 +− 2.3 pmol/mg
respectively (P < 0.01) with corresponding K i values of 1.13 +− 0.37 and 0.811 +− 0.34 nM
respectively.
and increase in GNX-4975-binding sites seen in the swelling
assay (Figure 2A) was also observed in the shrinkage assay. In all
cases, the initial 20 min of pre-swelling was carried out in KSCN
buffer and the mitochondria were maintained in KSCN buffer
after their isolation by centrifugation. However, the mitochondria
were then resuspended in the appropriate buffer (KSCN or KCl)
for the shrinkage assay. Data are shown in Figure 5B and, in
Figure 6 When GNX-4975 is added after Ca2+ its K i for inhibition of MPTP
opening is greatly reduced
In (A), prior to initiation of shrinkage with PEG 2000, pre-swollen mitochondria (2 mg total)
were incubated in KSCN medium without [Ca2 + ] (1), with 50 μM Ca2 + for 1 min (2) or
2 min (3) with 0.1 μM GNX-4975 for 1 min and then 50 μM Ca2 + for 1 min (4), with 50 μM
Ca2 + for 1 min and then 0.1 μM GNX-4975 for 1 min (5) or both 50 μM Ca2 + and 0.1 μM
GNX-4975, added simultaneously, for 2 min (6). Initial rates of swelling were expressed as a
percentage of rates obtained with 2 min Ca2 + only (3) and as mean values (+−S.E.M., error bars)
for six separate mitochondrial preparations (*P < 0.001 in comparison with data for condition
2; #P < 0.001 compared with conditions 4 and 5; $P < 0.001 compared with condition 4). In
(B), pre-swollen mitochondria (1 or 2 mg total, as indicated) were incubated in 3 ml KSCN
medium with 50 μM Ca2 + for 1 min followed by increasing concentrations of GNX-4975 prior
to initiation of shrinkage with PEG 2000. Initial rates of shrinkage, expressed as a percentage
of the rate in the absence of inhibitor, are shown as means +− S.E.M. (error bars) of three
separate mitochondrial preparations and were fitted to a conventional hyperbolic inhibition
curve (see ‘Experimental’). The derived K i values (+−S.E.M. for the fit shown) were 117 +− 15
and 166 +− 29 nM for 1 and 2 mg of protein respectively. For comparison, data from Figure 5B
(closed triangles) have been included to illustrate that GNX-4975 is much more effective when
added before Ca2 + .
agreement with the swelling data (Figure 2A), the number of
GNX-4975-binding sites (pmol/mg; mean +− S.E.M. for three
separate preparations) increased from 29.6 +− 2.3 in the KCl buffer
to 49.0 +− 2.8 in KSCN buffer (P < 0.01) without a significant
change in K i (0.81 +− 0.34 and 1.13 +− 0.37 nM respectively).
Having validated the shrinkage assay for measurement of GNX-
4975 binding to the MPTP, we employed it to see whether the
order of addition of Ca2 + and GNX-4975 affected the potency
of the inhibitor. The data of Figure 6A show that when 0.1 μM
GNX-4975 was added to pre-swollen mitochondria after 50 μM
Ca2 + , it was much less potent at inhibiting MPTP opening
(34 +− 3.8% inhibition) than when added before Ca2 + (93 +− 0.4%
inhibition). Even when added simultaneously with 50 μM Ca2 +
there was some reduction in inhibition (85 +− 1.0% inhibition). In
Figure 6B, we compare the concentration dependence of GNX-
4975 inhibition when added before or after 50 μM Ca2 + . In the
former case, the number of GNX-4975-binding sites and their
K i were determined in Figure 5B as 49.0 +− 2.8 pmol/mg and
1.13 +− 0.37 nM respectively (data are means +− S.E.M. for three
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Table 1 Collated Et and K i values for GNX-4975 binding
The concentration of GNX-4975-binding sites (E t in pmol/mg) and their K i values (nM) are taken from the figures indicated. Where data for a particular condition are available from several figures
(such as for KSCN buffer, 50 μM Ca2 + ), the value presented is the mean +− S.E.M. for all of the mitochondrial preparations used. The ‘Conditions’ column indicates whether the data are from
the swelling or shrinkage experiment, the buffer and [Ca2 + ] used and the concentration of any MPTP modulators (if present). In the right-hand column, the data presented show the number of
GNX-4975-binding sites (E t in pmol/mg) calculated with a fixed K i that is derived from the mean of all K i values calculated under the different swelling and shrinkage conditions (1.80 +− 0.079,
n = 61).
Conditions Figure n K i (nM) E t (pmol/mg) E t (pmol/mg) at fixed K i
Swelling assay
KCl, 150 μM Ca2 + 2A 5 1.68 +− 0.13 9.43 +− 1.4 9.10 +− 1.5
KSCN, 50 μM Ca2 + , 5 μM BKA 3A 6 1.46 +− 0.16 9.43 +− 0.47 8.56 +− 1.7
KSCN, 50 μM Ca2 + , 20 μM ADP 3B 6 1.45 +− 0.15 11.0 +− 0.97 10.1 +− 1.1
KSCN, 50 μM Ca2 + 2A, 2B, 3A, 3B, 4 23 1.71 +− 0.13 13.1 +− 0.60 12.9 +− 0.59
KSCN, 50 μM Ca2 + , 20 μM PAO 2B 6 2.56 +− 0.14 17.2 +− 1.3 19.5 +− 1.6
KSCN, 150 μM Ca2 + 2A 10 2.22 +− 0.15 20.1 +− 1.3 21.4 +− 1.4
Shrinkage assay
KCl, 50 μM Ca2 + 5B 3 0.81 +− 0.34 29.6 +− 2.3 22.1 +− 3.8
KSCN, 50 μM Ca2 + 5B 3 1.13 +− 0.37 49.0 +− 2.8 45.7 +− 5.2
separate experiments). However, when Ca2 + was added prior to
the GNX-4975, the potency of the inhibitor was far less and
independent of protein concentration. The data could now be
fitted to the normal equation for inhibition (rate as% control =
100/(1 + [I]/K i)) with the derived K i values at 1 and 2 mg of
total protein being 117 +− 15 and 166 +− 29 nM respectively (data
are means +− S.E.M. for three separate experiments; P > 0.05).
GNX-4975 binds only to the active conformation of the MPTP
In Table 1, we present data for the calculated number of GNX-
4975-binding sites and the associated K i values under all the
conditions used in the present study. Reassuringly, differences
in the calculated K i values are small. We confirmed that these
differences in the calculated K i values could not account for any
differences in calculated Et values by re-analysing the data for
each experimental condition using a fixed value of K i (1.8 nM
– the mean of the values obtained in the swelling experiments).
These data are also included in Table 1. In Figure 7, we plot the
calculated mean number of GNX-4975-binding sites determined
under each condition with the mean absolute rate of swelling
determined under the same conditions and demonstrate a very
significant linear correlation (two-tailed Pearson’s correlation
coefficient (r) of 0.743; P < 0.001). This strongly supports the
hypothesis that GNX-4975 binds to the open pore complex and
that a variety of agents that enhance or reduce MPTP opening
do so by increasing or decreasing this active conformation of the
MPTP. By contrast, titration of MPTP opening with CsA always
produces the same number of binding sites irrespective of the
degree of activation because it inhibits by interacting with CyP-D
in its native conformation, preventing its binding to the membrane
component(s) of the MPTP [28,29,41]. Since the number of GNX-
4975-binding sites varies according to the activation state of the
MPTP, it seems probable that this reflects a small fraction of
a membrane protein (or proteins) undergoing a conformation
change to form the pore.
GNX-4975 stabilizes an interaction between the ANT and the PiC in
heart IMM membranes
We have suggested previously that both the ANT and PiC may
be implicated in MPTP formation, with the pore forming at the
interface of these two proteins in a novel conformation [1]. If
this were the case, then GNX-4975 might bind at this interface
and stabilize the interaction between the two proteins. In order to
Figure 7 Control rates of swelling correlate with the calculated number of
GNX-4975-binding sites as MPTP activity is increased
For each condition shown in Table 1, absolute rates of swelling were calculated and plotted from
the derived values of E t and the rate constant k . Mean values were then calculated (+−S.E.M.
as vertical error bars) and plotted against the mean values of E t (+−S.E.M. as horizontal error
bars). A total of 55 different data points are represented and were used to calculate a Pearson’s
correlation coefficient (r) of 0.743 (P < 0.001).
investigate this possibility, we made use of the observation that, for
solubilized beef heart IMMs, both proteins bind to immobilized
PAO. Binding of both proteins is prevented by the ubiquinone
(UQ) analogues, UQ0 and Ro 68-3400, that inhibit MPTP opening,
whereas binding of the ANT is specifically prevented by CAT
that traps the ANT in its ‘c’ conformation [10,12,42]. Since
CAT is associated with enhanced MPTP opening, it would be
predicted that some ANT might remain bound to the PAO column
in the presence of GNX-4975 to stabilize its interaction with
the PiC. The data of Figure 8 confirm this to be the case for
solubilized IMMs from both pig and beef heart mitochondria.
As expected, treatment of heart mitochondria with 10 μM CAT
prior to IMM isolation and solubilization totally prevented ANT
binding to the PAO column. However, when either beef or pig heart
mitochondria were treated with 10 μM CAT followed by 1 μM
GNX-4975 prior to IMM isolation and solubilization, some ANT
remained bound to the PAO column, consistent with the inhibitor
stabilizing an interaction between the ‘c’ conformation of the
ANT and the PiC or another IMM protein bound to the column.
Underneath each blot, we give the integrated optical density for
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Table 2 Orbitrap MS analysis of proteins specifically eluted from immobilized PAO
Binding of solubilized bovine heart mitochondria to immobilized PAO was carried out as described in the Experimental section. Specifically bound proteins were eluted using DTT, run 1 cm into a
12 % acrylamide gel and analysed by Orbitrap MS as outlined in the Experimental section. The protein area column uses the three peak method of quantification to determine the relative amount of
each protein in the sample. To calculate each individual protein contribution towards the total eluted protein as a percentage, each protein area score was standardized to the sum of all area scores
for all of the protein hits eluted (295.43). Data for all 664 proteins detected are available online in a Supplementary Excel file.
Molecular mass (kDa) Description Protein score Percentage of total protein
Most abundant proteins
32.9 ADP/ATP translocase 1 34.78 11.77
35.0 Phosphate carrier protein 11.97 4.05
111.3 2-Oxoglutarate dehydrogenase 8.11 2.75
9.3 NADH dehydrogenase (ubiquinone) 1 α subcomplex subunit 4 7.34 2.48
47.9 Keratin, type I cytoskeletal 18 7.31 2.47
36.7 NADH dehydrogenase (ubiquinone) 1 α subcomplex subunit 10 7.12 2.41
36.7 NDUFA10 protein (fragment) 5.49 1.86
33.2 D-β-Hydroxybutyrate dehydrogenase 5.14 1.74
63.1 Keratin, type II cytoskeletal 1 4.73 1.60
68.7 Stress-70 protein 4.70 1.59
31.6 Voltage-dependent anion-selective channel protein 2 4.20 1.42
47.2 Creatine kinase S-type 4.16 1.41
ATP synthase subunits
55.2 ATP synthase subunit α 0.86 0.29
51.6 ATP synthase subunit β 0.81 0.27
30.3 ATP synthase subunit γ 0.36 0.12
24.7 ATP synthase subunit b 0.26 0.09
20.9 ATP synthase subunit OSCP (oligomycin-sensitivity-conferring protein) 0.22 0.08
18.7 ATP synthase subunit d 0.19 0.06
15.1 ATP synthase subunit δ 0.14 0.05
Figure 8 The effects of GNX-4975 on the binding to immobilized PAO of the
ANT and PiC from control and CAT-treated heart mitochondria
Binding of solubilized beef and pig heart IMM proteins to immobilized PAO was carried out
as described in the Experimental section. Identical amounts of solubilized IMMs were added
to the immobilized PAO in each case and specifically bound proteins were eluted using DTT
and analysed by Western blotting using ANT- and PiC-specific antibodies as indicated. Only
the section of the blot of ∼30 kDa is shown since no other significant bands were detected.
Two separate experiments are shown for both beef and pig mitochondria and the values beneath
each blot represent the integrated optical density for each band visualized on film and scanned.
This was determined as described in the Experimental section and expressed as a percentage
of the value for the untreated sample. The bottom blots represent samples from Experiment 1
re-analysed using an ODDESEY Fc (LI-COR) to directly detect the ECL signal. Lanes are: (1)
untreated, (2) 1 μM GNX-4975 treated, (3) 10 μM CAT treated, (4) treated with 10 μM CAT
followed by 1 μM GNX-4975.
each band, calculated as the product of the ‘area’ and ‘mean grey
value’ with appropriate background subtraction as described in
the Experimental section, which reveals that the amount of the
ANT bound after CAT treatment in the presence of GNX 4975
as a percentage of the total ANT bound in the absence of CAT is
4.51 +− 0.33% (mean +− S.E.M., n = 4 comprising the two beef
and two pig experiments shown). This value is likely to be an
overestimate because the amount of ANT remaining after CAT in
the presence of GNX 4975 is very small and thus requires a long
film exposure to visualize the band. This causes the intensity of
the ANT band in the absence of CAT to exceed the linear response
of the film. Indeed, in the bottom panel, we have re-analysed the
blots for one set of pig and one set of beef mitochondria using an
ODDESEY Fc (LI-COR) to directly detect the ECL signal. These
data suggest that the overestimate is by a factor of ∼1.65 in both
the pig and beef samples. From these data, we can estimate the
amount of ANT whose binding is enhanced by GNX-4975 to be
∼2.7% of the total.
In order to establish whether other proteins that have been
proposed to be part of the MPTP, such as subunits of the F1Fo-
ATP synthase, might act as a binding partner for the ANT, we
performed a proteomic analysis using Orbitrap MS to identify
all IMM proteins from beef heart mitochondria that bound to
the PAO column. Full data are provided as a Supplementary
Excel file but Table 2 presents the 12 most abundant proteins
(each >1% of total protein bound) and, in addition, those
components of the F1Fo-ATP synthase that were detected (α, β,
γ , b, oligomycin-sensitivity-conferring protein (OSCP), d and δ
subunits). As reported previously, the dominant proteins were the
ANT (11.8%) and PiC (4.1%), whereas the F1Fo-ATP synthase
subunits bound at levels similar to a range of other IMM proteins
(<0.3%). This makes them less attractive candidates for the
MPTP than the PiC and ANT and very unlikely targets for the site
of PAO activation on the pore.
DISCUSSION
The exact molecular composition of the membrane component
of the MPTP remains uncertain with evidence presented for a
regulatory or structural involvement of the ANT, PiC, different
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components of the F1Fo-ATP synthase and, most recently, the
inner membrane AAA protease SPG7 [1,4,6,7,25,26]. Irrespective
of the exact composition of the MPTP, it seems unlikely that any
of these proteins form the pore in their normal conformation
since their concentrations are far higher than the number of
GNX-4975-binding sites determined here (9–50 pmol/mg of
mitochondrial protein depending on the degree of activation).
Thus the concentration of ANT in rat liver and bovine heart
mitochondria is 0.3 and 1.2 nmol/mg respectively [43], whereas
for the PiC values of 0.28 and 0.67 nmol/mg have been
estimated [44]. The concentration of the F1Fo-ATP synthase is
∼0.2 nmol/mg in rat liver mitochondria [45] and for CyP-D values
of ∼100–200 pmol/mg in rat liver and heart mitochondria have
been estimated [28,46].
GNX-4975 binds only to the active MPTP at the Ca2+ activation site
Our data demonstrate that GNX-4975 is a potent MPTP inhibitor
(K i ∼ 1.8 nM) that binds only to the active (open) form of the
pore. The data, summarized in Table 1 and Figure 7, show that
activators of the MPTP such as PAO, KSCN and higher [Ca2 + ]
increase the number of inhibitor-binding sites, whereas the BKA
and ADP that reduce MPTP opening decrease the number of
GNX-4975-binding sites. None of these effectors caused a major
change in the K i of GNX-4975 for inhibition of MPTP opening
provided the inhibitor was added before Ca2 + as in the swelling
assay for MPTP opening. However, using the shrinkage assay, it
was shown that if Ca2 + was added prior to GNX-4975 the K i was
greatly elevated (Figure 6). The simplest explanation for these
data would be that [Ca2 + ] and GNX-4975 compete for the same
binding site on the active conformation of the MPTP, but that
once GNX-4975 is bound its dissociation is so slow that Ca2 +
cannot displace it within the timeframe of the experiment. Such
behaviour is well documented for tight binding inhibitors [47],
and a low off rate constant (koff) has also been observed for CsA
binding [41,48]. The koff could be determined from the K i if the
rate constant for inhibitor binding (kon) was known, since K i =
koff/kon. Values of kon for tight inhibitor binding to soluble enzymes
have been shown to range between 104 and 109 mol− 1 · l− 1 · s− 1
and can be substantially lower where inhibitor binding produces
a conformation change [47]. For a kon of 105 mol− 1 · l− 1 · s− 1 the
calculated koff is 2 × 10− 4 s− 1 implying that it would take nearly
1 h for 50% dissociation of the inhibitor and thus that Ca2 +
would not displace the GNX-4975 during the time of the assay.
This would explain the low K i values observed when the inhibitor
was added prior to Ca2 + , but considerably higher values when the
order of addition was reversed.
The open MPTP is formed when a small fraction of an IMM protein
adopts a novel conformation
Although CsA and GNX-4975 exhibit similar K i values for
inhibition of the MPTP, they act quite differently. CsA binds to
CyP-D and prevents its association with a membrane component
of the MPTP that facilitates the calcium-activated conformational
change required for pore opening [1,4,6,25]. As such the number
of CsA-binding sites determined from inhibitor titrations of
MPTP opening always matches the amount of CyP present
in the mitochondrial matrix [28,29]. Conversely, for GNX-
4975 the number of binding sites varies depending on the
activity of the MPTP. This can be explained if formation of
the active MPTP requires a fraction of a native IMM protein
(or proteins) to adopt a novel conformation to which GNX-4975
binds. The concentration of GNX-4975-binding sites determined
in liver mitochondria varied between 9 and 20 pmol/mg of
protein depending on conditions in normal de-energized liver
mitochondria, and increased up to ∼50 pmol/mg of protein in pre-
swollen mitochondria (Table 1). Thus the IMM component(s) that
form the MPTP must be present in concentrations significantly
higher than this which is true of the proposed candidate proteins,
the PiC, ANT and subunits of the F1Fo-ATP synthase as noted
above.
GNX-4975 stabilizes an interaction between the PiC and the ANT in
its ‘c’ conformation
We have previously proposed that the MPTP may be formed at the
interface between the ANT and the PiC when one or both of these
proteins is in a distinct conformation such as the ‘c’ conformation
of the ANT and the PiC modified by oxidative stress or PAO [1].
This would be entirely consistent with the GNX-4975-binding
studies discussed above and received further support from the
effects of CAT and GNX-4975 on the binding of IMM proteins to
immobilized PAO shown in Figure 8. We have previously shown
that PAO activates the MPTP by binding to vicinal thiol groups
on both the ANT and PiC [10,12,37]. If the MPTP is formed
when such an interaction occurs between the PAO-bound PiC
and the ANT in the ‘c’ conformation, then a small fraction of
the ANT might remain attached to the PiC on the column if this
interaction survived the solubilization process. This was observed
in the presence of GNX-4975 but not in its absence (Figure 8
and Table 2), suggesting that inhibitor binding may stabilize the
interaction between the two proteins. The relatively small amount
(2.7%) of the ANT bound compared with the total ANT bound in
the absence of CAT is to be expected since the GNX-4975-binding
data suggest only ∼10–20 pmol/mg of protein of the active
MPTP complex compared with a concentration of the ANT of
300 and 1200 nmol/mg in rat liver and bovine heart mitochondria
respectively [43]. Other proteins that have been proposed to be
important in MPTP formation, such as subunits of the F1Fo-ATP
synthase [4,7] and the mitochondrial AAA protease SPG7 [26],
were either not detected in the protein fraction bound to the PAO or
were present at extremely low levels (<0.3%) compared with the
ANT and PiC (11.8 and 4.1% respectively) as shown in Table 2.
Although this does not rule out their role in MPTP formation,
it does suggest that these proteins are unlikely to contain
the vicinal thiol groups whose binding of PAO activates the
MPTP.
Insights into the molecular mechanism of the MPTP
The data we have obtained with GNX-4975 are entirely consistent
with previous data from our laboratory, reviewed in [1], that
led us to propose that such conformational changes in both
the ANT and PiC may induce an interface between these two
membrane proteins, perhaps involving their tightly bound annular
cardiolipin and co-ordinated by the F1Fo-ATP synthase in the
proposed ATP synthasome complex. The ANT provides the bin-
ding site for regulation by adenine nucleotide, ligands of the ANT
and oxidative stress as has been demonstrated by the loss of
such regulation in mitochondria lacking ANT1 and ANT2 [17].
Furthermore, the reconstituted ANT can form Ca2 + -activated
channels that are regulated by CyP-D [16,49]. Involvement of
the PiC can account for the activation of the MPTP by Pi and its
inhibition by low concentrations of N-ethylmaleimide, as well as
providing an additional site of action of oxidative stress and PAO
[10,14]. We have further proposed that Ca2 + may act through
its binding to annular cardiolipin at the interface between the
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Figure 9 A schematic diagram showing a plausible mechanism for the MPTP and its inhibition by GNX-4975
In their cytosol-facing (‘c’) conformation, such as when stabilized by CAT or oxidative stress, IMM candidate proteins for the MPTP such as the ANT and PiC can undergo a further conformation
change that is enhanced by KSCN and Pi and to which CyP-D can bind. This produces an interface between the two proteins, perhaps involving cardiolipin that represents the MPTP in its closed state.
Binding of Ca2 + on the matrix face triggers a further conformation change, facilitated by CyP-D (thick arrows cf. thin arrows), to open the MPTP. GNX-4975 binds to the closed MPTP, stabilizing this
conformation and so preventing Ca2 + from triggering pore opening which is reversible. The equilibrium between open and closed states is determined by the [Ca2 + ] whose action is competitively
inhibited by GNX-4975 binding. However, the rate of dissociation of GNX-4975, once bound, is very low and thus not readily overcome by increasing [Ca2 + ].
PiC and the ANT [1]. Indeed, cardiolipin is one of the few
calcium-binding molecules that can distinguish between Sr2 +
and Ca2 + [50] which may explain why the MPTP is activated
by Ca2 + , but not Sr2 + [40]. Our present data suggest that GNX-
4975 binds to the active form of the MPTP in competition
with Ca2 + at this interface. This is illustrated schematically in
Figure 9.
Despite this evidence in favour of our model, it cannot
be ignored that knockdown of either the ANT or the PiC
only attenuates MPTP activity and modulates its regulatory
properties. These data demonstrate that neither the PiC nor the
ANT is indispensable for MPTP activity, implying that other
proteins can form the MPTP. However, the PiC and ANT are
members of the 53-strong mitochondrial carrier family (MCF)
which share a common structure in which six transmembrane
helices form the substrate translocation pathway that involves
conformational changes between inward- and outward-facing
conformations [51]. Thus it is possible that any member of
the MCF can enter a conformation in which they form an
interface with another MCF member to form the MPTP. Annular
cardiolipin is likely to surround all MCF members and thus
could provide a common Ca2 + -binding site whatever MCF
members form the pore. Nevertheless, because the ANT and
PiC are by far the most prevalent MCF members and may
already be in close association through the ATP synthasome,
they will usually form the MPTP and account for its regulation
by adenine nucleotide, ANT ligands, PAO, oxidative stress
and Pi [1].
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